Cargando…

Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods

INTRODUCTION: A standardised method for quantifying β-amyloid PET tracers would allow comparison across different tracers and different sites. The development of the Centiloid scale has aimed to achieve this, applying a common scale to better aid the diagnosis and prognosis of Alzheimer’s disease (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Battle, Mark R., Pillay, Lovena Chedumbarum, Lowe, Val J., Knopman, David, Kemp, Bradley, Rowe, Christopher C., Doré, Vincent, Villemagne, Victor L., Buckley, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281542/ https://www.ncbi.nlm.nih.gov/pubmed/30519791 http://dx.doi.org/10.1186/s13550-018-0456-7

Ejemplares similares

(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids
por: Rowe, Christopher C., et al.
Publicado: (2017)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

A universal neocortical mask for Centiloid quantification
por: Bourgeat, Pierrick, et al.
Publicado: (2023)

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study
por: Hanseeuw, Bernard J., et al.
Publicado: (2020)

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
por: Amadoru, Sanka, et al.
Publicado: (2020)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
por: Lowe, Val J., et al.
Publicado: (2017)

Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values
por: Schwarz, Christopher G., et al.
Publicado: (2018)

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images
por: Bucci, Marco, et al.
Publicado: (2021)

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Validation of an electronic image reader training programme for interpretation of [(18)F]flutemetamol β-amyloid PET brain images
por: Buckley, Christopher J., et al.
Publicado: (2017)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

Centiloid method evaluation for amyloid PET of subcortical vascular dementia
por: Yun, Hyuk Jin, et al.
Publicado: (2017)

Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

Is Amyloid Burden Measured by (18)F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
por: Müller, Ebba Gløersen, et al.
Publicado: (2022)

Simulating the effect of cerebral blood flow changes on regional quantification of [(18)F]flutemetamol and [(18)F]florbetaben studies
por: Heeman, Fiona, et al.
Publicado: (2020)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Author Correction: Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Feasibility evaluation of middle-phase (18)F-florbetaben positron emission tomography imaging using centiloid quantification and visual assessment
por: Wu, Cheng-Han, et al.
Publicado: (2023)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

[(18)F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [(18)F]-Fludeoxyglucose
por: Kalheim, Lisa Flem, et al.
Publicado: (2018)

Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease
por: Ikonomovic, Milos D., et al.
Publicado: (2020)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamol-amyloid-PET recordings
por: Völter, Friederike, et al.
Publicado: (2022)

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
por: Royse, Sarah K., et al.
Publicado: (2021)

Development and clinical validation of CT-based regional modified Centiloid method for amyloid PET
por: Kim, Soo-Jong, et al.
Publicado: (2022)

Initial Physician Experience with [(18)F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
por: Hattori, Naoya, et al.
Publicado: (2020)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
por: Son, Hye Joo, et al.
Publicado: (2018)

Development of software for measuring brain amyloid accumulation using (18)F‐florbetapir PET and calculating global Centiloid scale and regional Z‐score values
por: Matsuda, Hiroshi, et al.
Publicado: (2023)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Luckett, Emma S., et al.
Publicado: (2023)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated
por: An, Young-Sil, et al.
Publicado: (2021)

Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
por: Salloway, Stephen, et al.
Publicado: (2017)

Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
por: Farrar, Gill, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_48ir4mcv24cqq96948qtm7gm1f